EBS Emergent BioSolutions Inc.

P/E --

Forward P/E 2.327

Price/Sales 0.415

Beta 2.286

Div Yield --

Market Cap --

Company Analysis

Latest News

November 04, 2026

EBS Awarded $22.3M Contract Modification to Supply Anthrax Vaccine to U.S. Military

Emergent BioSolutions announced it has received a modification exercising an option period under an existing delivery order from the U.S. Department of War....

November 02, 2026

Emergent BioSolutions misses third quarter revenue estimates and lowers full-year 2026 guidance

Emergent BioSolutions reported third quarter 2026 results that met the low end of management's own guidance but missed analyst consensus, primarily due to...

November 01, 2026

Emergent BioSolutions Inc Q3 2026 Earnings Preview: What Analysts Expect on November 02, 2026

Consensus estimates for Emergent BioSolutions indicate Q3 2026 revenue of $123.22 million and an adjusted EPS loss of $0.45, with the current $6.81 stock price...